Need professional-grade analysis? Visit stockanalysis.com
$1.71B
N/A
N/A
N/A
Trevi Therapeutics Inc (TRVI) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $14.62, down 4.01% from the previous close.
Over the past year, TRVI has traded between a low of $5.47 and a high of $15.23. The stock has gained 133.2% over this period. It is currently 167.3% above its 52-week low.
Trevi Therapeutics Inc has a market capitalization of $1.71B.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Side-by-side comparison against top Healthcare peers.